Nanogen Issued Patent for Device That Combines Optical Waveguides and Molecular Diagnostics

Nov 23, 2004, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of advanced diagnostic products, announced today that it was issued
 U.S. Patent No. 6,821,729, "Device for Molecular Biological Analysis and
 Diagnostics Including Waveguides," by the U.S. Patent and Trademark Office.
 The '729 patent covers methods and technologies for coupling optical
 waveguides with a DNA microarray used for performing biological operations and
 illuminating it at an angle that allows the size and complexity of the
 diagnostic instrument to be reduced.  Nanogen continues to build its patent
 portfolio with the '729 patent marking the company's 78th patent issued in the
     Common fluorescent detection systems utilize excitation light that arrives
 at the face of a DNA chip at an angle, which requires a greater working
 distance.  This patent allows for new positioning of a chip's components,
 including the substrate, top and edges, so that light is delivered via
 integrated waveguides, thus enabling a smaller and more compact device design.
 This technology also improves fluorescent detection by reducing the amount of
 excitation light that is reflected back into the sensor array.
     "Nanogen continues to develop technologies that allow us to reduce the
 complexity and shrink the footprints of molecular diagnostic systems," said
 Howard C. Birndorf, Nanogen chairman and chief executive officer.  "This
 intellectual property asset can be leveraged by Nanogen for potential product
 development or by other innovators who, for example, are creating optical
 waveguides using DNA chips and microscope slides for molecular analysis."
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarrays
 and analyte specific reagents to develop tests to detect mutations associated
 with genetic diseases.  The next generation instrument system, the NanoChip(R)
 400, is expected to be available in 2005.  Nanogen's subsidiary SynX offers a
 line of point-of-care diagnostic tests and is building expertise in cardiac
 related health conditions.  Nanogen's ten years of pioneering research
 involving nanotechnology may also have future applications in medical
 diagnostics, biowarfare and other industries.  For additional information
 please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether Nanogen's NanoChip(R) System can be
 successfully further commercialized, whether other products under development
 can be successfully developed and commercialized, whether results reported by
 our customers or partners can be identically replicated, whether ASRs
 currently sold by Nanogen will become FDA-approved molecular diagnostic test
 kits, whether Nanogen will be successful in developing additional ASRs and
 protocols utilizing the NanoChip(R) System, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.